Hemolytic uremic syndrome/thrombotic thrombocytopenic purpura

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Hemolytic uremic syndrome (HUS) and thrombotic thrombocytopenic purpura (TTP) are thrombotic microangiopathies (TMAs) manifesting with thrombocytopenia and microangiopathic hemolytic anemia. TMA have either an acquired or a genetic origin. The most common form of TMA is Shigatoxin-associated HUS, which is caused by certain strains of bacteria that produce exotoxins, the Shiga-like toxins causing endothelial damage. This form has generally a good outcome with supportive therapy. Immune-mediated HUS and TTP are caused by the formation of autoantibodies against complement factor H or ADAMTS-13, respectively. These forms benefit from plasma exchange combined with immunosuppressive treatments. Treatment of forms secondary to systemic diseases rests on specific treatments of the underlying condition. Genetic predisposition to HUS is determined by mutations in genes encoding complement regulatory proteins. The outcome is poor. Some forms respond to plasma treatment. Genetic deficiency of ADAMTS13 is associated with congenital TTP. This form benefits from plasma therapy.

Original languageEnglish
Title of host publicationManagement of Acute Kidney Problems
PublisherSpringer Berlin Heidelberg
Pages349-364
Number of pages16
ISBN (Print)9783540694137
DOIs
Publication statusPublished - 2010

Fingerprint

Thrombotic Thrombocytopenic Purpura
Hemolytic-Uremic Syndrome
Thrombotic Microangiopathies
Therapeutics
Shiga Toxins
Complement Factor H
Exotoxins
Plasma Exchange
Hemolytic Anemia
Genetic Predisposition to Disease
Immunosuppressive Agents
Thrombocytopenia
Autoantibodies
Complement System Proteins
Bacteria
Mutation
Genes

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Hemolytic uremic syndrome/thrombotic thrombocytopenic purpura. / Noris, Marina; Galbusera, Miriam; Remuzzi, Giuseppe.

Management of Acute Kidney Problems. Springer Berlin Heidelberg, 2010. p. 349-364.

Research output: Chapter in Book/Report/Conference proceedingChapter

Noris, Marina ; Galbusera, Miriam ; Remuzzi, Giuseppe. / Hemolytic uremic syndrome/thrombotic thrombocytopenic purpura. Management of Acute Kidney Problems. Springer Berlin Heidelberg, 2010. pp. 349-364
@inbook{1e99018c2bc44f9497757a707e13be55,
title = "Hemolytic uremic syndrome/thrombotic thrombocytopenic purpura",
abstract = "Hemolytic uremic syndrome (HUS) and thrombotic thrombocytopenic purpura (TTP) are thrombotic microangiopathies (TMAs) manifesting with thrombocytopenia and microangiopathic hemolytic anemia. TMA have either an acquired or a genetic origin. The most common form of TMA is Shigatoxin-associated HUS, which is caused by certain strains of bacteria that produce exotoxins, the Shiga-like toxins causing endothelial damage. This form has generally a good outcome with supportive therapy. Immune-mediated HUS and TTP are caused by the formation of autoantibodies against complement factor H or ADAMTS-13, respectively. These forms benefit from plasma exchange combined with immunosuppressive treatments. Treatment of forms secondary to systemic diseases rests on specific treatments of the underlying condition. Genetic predisposition to HUS is determined by mutations in genes encoding complement regulatory proteins. The outcome is poor. Some forms respond to plasma treatment. Genetic deficiency of ADAMTS13 is associated with congenital TTP. This form benefits from plasma therapy.",
author = "Marina Noris and Miriam Galbusera and Giuseppe Remuzzi",
year = "2010",
doi = "10.1007/978-3-540-69441-0_36",
language = "English",
isbn = "9783540694137",
pages = "349--364",
booktitle = "Management of Acute Kidney Problems",
publisher = "Springer Berlin Heidelberg",

}

TY - CHAP

T1 - Hemolytic uremic syndrome/thrombotic thrombocytopenic purpura

AU - Noris, Marina

AU - Galbusera, Miriam

AU - Remuzzi, Giuseppe

PY - 2010

Y1 - 2010

N2 - Hemolytic uremic syndrome (HUS) and thrombotic thrombocytopenic purpura (TTP) are thrombotic microangiopathies (TMAs) manifesting with thrombocytopenia and microangiopathic hemolytic anemia. TMA have either an acquired or a genetic origin. The most common form of TMA is Shigatoxin-associated HUS, which is caused by certain strains of bacteria that produce exotoxins, the Shiga-like toxins causing endothelial damage. This form has generally a good outcome with supportive therapy. Immune-mediated HUS and TTP are caused by the formation of autoantibodies against complement factor H or ADAMTS-13, respectively. These forms benefit from plasma exchange combined with immunosuppressive treatments. Treatment of forms secondary to systemic diseases rests on specific treatments of the underlying condition. Genetic predisposition to HUS is determined by mutations in genes encoding complement regulatory proteins. The outcome is poor. Some forms respond to plasma treatment. Genetic deficiency of ADAMTS13 is associated with congenital TTP. This form benefits from plasma therapy.

AB - Hemolytic uremic syndrome (HUS) and thrombotic thrombocytopenic purpura (TTP) are thrombotic microangiopathies (TMAs) manifesting with thrombocytopenia and microangiopathic hemolytic anemia. TMA have either an acquired or a genetic origin. The most common form of TMA is Shigatoxin-associated HUS, which is caused by certain strains of bacteria that produce exotoxins, the Shiga-like toxins causing endothelial damage. This form has generally a good outcome with supportive therapy. Immune-mediated HUS and TTP are caused by the formation of autoantibodies against complement factor H or ADAMTS-13, respectively. These forms benefit from plasma exchange combined with immunosuppressive treatments. Treatment of forms secondary to systemic diseases rests on specific treatments of the underlying condition. Genetic predisposition to HUS is determined by mutations in genes encoding complement regulatory proteins. The outcome is poor. Some forms respond to plasma treatment. Genetic deficiency of ADAMTS13 is associated with congenital TTP. This form benefits from plasma therapy.

UR - http://www.scopus.com/inward/record.url?scp=84895325765&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84895325765&partnerID=8YFLogxK

U2 - 10.1007/978-3-540-69441-0_36

DO - 10.1007/978-3-540-69441-0_36

M3 - Chapter

AN - SCOPUS:84895325765

SN - 9783540694137

SP - 349

EP - 364

BT - Management of Acute Kidney Problems

PB - Springer Berlin Heidelberg

ER -